Amp Volatility Score
Catalyst Info & Data Links
TITLE: Lonafarnib (Ritonavir) for Hepatitis Delta Virus
ClinicalTrials.gov (NCT03719313) Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a (D-LIVR)
WHAT IS THE CATALYST EVENT?
Phase 3 D-LIVR study full enrollment expected in 2021
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
11-12-2020 Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
MECHANISM OF ACTION
After HDV enters a target cell hepatocyte, the genome is translocated to the nucleus where genome replication occurs without the need of any gene products from HBV. An important interaction between HDV and HBV proteins has been shown to depend on the presence of the last 4 amino acids of the large delta antigen, comprising a CXXX box motif, where C represents cysteine and X denotes any other amino acid. This amino acid sequence is required for the protein to be post-translationally modified by farnesyltransferase (FT), an enzyme which covalently attaches a 15-carbon prenyl-lipid farnesyl moiety to the cysteine of the CXXX box. Prenylation of the large delta antigen renders it more lipophilic, promotes its association with HBsAg, and is essential for initiating the HDV particle formation process.
Updated by JM
#EIGR, EIGER, HDV, Hepatitis Delta Virus Infection, Lonafarnib/Ritonavir for HDV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post